Table 2.

Characteristics of the FLS patients with positive tTG serology or known celiac disease

	Patient A	Patient B	Patient C	Patient D	Patient E
Age	64	50	68	76	60
Gender	Female	Female	Female	Male	Male
Length (cm)	163.3	162	164.6	178	183.5
Weight (kg)	81.9	62.2	69.7	85	86
BMI	30.71	23.7	25.73	26.83	25.54

Fracture (center)	Minor	Minor	Major	Minor	Minor
Fracture location	Radial head	Distal radius	Tibial plateau	Tarsal bone	Midshaft ulnar
BMD (T-scores)
Lumbar spine	− 2.6	− 2.9	− 0.2	− 1.7	− 0.7
Femoral neck	− 2.4	− 2.2	− 1.2	− 2.3	− 0.2
Total hip	− 2.2	− 0.8	− 0.4	− 1.8	0

BMD	Osteoporosis	Osteoporosis	Osteopenia	Osteopenia	Normal BMD
Vertebral fractures (VFA)	No VF	No VF	Th11 grade 1	Th12 grade 3	No VF
Self-reported calcium intake mg/day	711	369	1169	1028	1020
Calcium (mmol/l)	2.35	2.46	2.43	2.42	2.34
Phosphate (mmol/l)	1.30	1.25	1.17	1.03	1.00
Albumin (g/l)	39	41	38	34.0	41.0
25-OH vitamin D (nmol/l)	75	101	29	83	60
PTH (pmol/l)	4.4	4.0	7.8	18.0	5.0
Hemoglobin (mmol/l)	7.4	8.0	8.3	8.2	8.8
IgA (g/l)	6.38	2.72	2.14	4.03	4.43
IgA anti-tTG (U/ml)	91.4	36.5	24.6	37.4	1.6
IgA anti-EMA	Positive	Positive	Positive	Not performed	Not performed
Duodenal biopsy	–	Marsh 3c	Marsh 3a	Marsh 3b	Marsh 3b
	Uncertain celiac disease	Proven celiac disease (new)	Proven celiac disease (new)	Proven celiac disease (known)	Proven celiac disease (known)
Osteoporosis treatment	Refused treatment	Start alendronic acid	No indication for treatment	Treated with risedronic acid	No indication for treatment

FLS fracture liaison service, BMI body mass index, BMD bone mineral density, VFA vertebral fracture assessment, PTH parathyroid hormone, IgA Immunoglobulin A, IgA anti-tTg anti-tissue transglutaminase antibodies, IgA anti-EMA anti-endomysial antibodies